secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001654954-23-006209
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata Therapeutics Q1 cash $8.8M; FDA agrees CMC supports Phase 3 for acne drug DMT310
--------------------------------------------------------------------------------

- Cash and cash equivalents $8.8M as of March 31, 2023, up from $6.2M at Dec 31, 2022.
- Raised $5.0M gross from March 2023 public offering of common stock and warrants.
- FDA agreed that CMC procedures are sufficient to initiate Phase 3 studies of DMT310 for moderate-to-severe acne.
- R&D expenses $1.2M for Q1 2023, down from $1.6M in Q1 2022; G&A $1.1M vs $1.2M.
- Expects cash to fund operations into Q1 2024; awaiting FDA feedback on End of Phase 2 meeting by June 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495423006209/0001654954-23-006209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495423006209/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-006209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer